Addressing anti-microbial resistance (including TB)
This flagship focuses on the global epidemic of antimicrobial resistance (AMR), which is one of the most pressing health issues of the modern age.
Worldwide, strains of deadly bacteria that were once controllable have evolved and become resistant to antibiotic drugs (antimicrobials) that were previously effective in eliminating them. The development of new antimicrobials that can effectively eradicate these rapidly spreading AMR strains is therefore a high priority.
The Maurice Wilkins Centre’s AMR flagship aims to produce novel antimicrobials that target a number of high priority drug-resistant bacterial pathogens including multidrug-resistant Gram-positive and Gram-negative pathogens, and Mycobacterium tuberculosis.
The flagship brings together researchers from a variety of disciplines, including clinical microbiology, molecular biology, transition state determination, computational studies, antimicrobial peptides and synthetic biology driven natural product approaches to develop new drugs AMR pathogens.
Successful drug candidates funded by the AMR flagship will be taken through preclinical development and then clinical trials to assess their efficacy and suitability in humans.